Know Cancer

or
forgot password

An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase


Phase 3
18 Years
N/A
Not Enrolling
Both
Chronic Myeloid Leukemia

Thank you

Trial Information

An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase


Inclusion Criteria:



Stratum 1:

1. Currently participating in Novartis study CAMN107A2109

2. Written signed and dated informed consent prior to any study procedures being
performed

Stratum 2:

1. Male or female

2. > 18 years

3. ECOG 0,1,2

4. ASL/ALT <= 2.5 ULN or <= 5.0 ULN

5. Alcaline Phosfatase <= 2.5 ULN

6. Serum Bilirrubin <= 1.5 ULN

7. Serum Creatinine <= 1.5 ULN or creatinine clearance >=50 ml/min / 24 hours

8. Serum Lipase <= 1.5 ULN

Exclusion Criteria:

Stratum 1 and stratum 2:

1. Reduction of the cardiac function

2. Use of Coumadin

3. Other severe medical concurrent conditions

4. Treatment with medications that prolonged the QT interval.

5. Mayor surgery 15 days before the inclusion in the protocol

6. Pregnant women or lactation

Other protocol-defined inclusion/exclusion criteria may apply

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maintain and monitor long-term hematological and cytogenetic responses previously obtained by patients participating in the CAMN107A2109 study.

Outcome Time Frame:

between 6 and 12 months

Safety Issue:

Yes

Principal Investigator

Novartis Pharmaceuticlas

Investigator Role:

Study Director

Investigator Affiliation:

Novartis Pharmaceuticals

Authority:

Colombia: Instituto Nacional De Vigilancia De Medicamentos y Alimentos

Study ID:

CAMN107ACO01

NCT ID:

NCT01126892

Start Date:

January 2009

Completion Date:

April 2011

Related Keywords:

  • Chronic Myeloid Leukemia
  • Advanced Disease,
  • Resistance,
  • Intolerance
  • Blast Crisis
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Name

Location